{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000025","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.364881+00:00","generated_at":"2026-05-25T06:20:19.965768+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules","bullets":["Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.","Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.","Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.","Conforming edits and other clarifying updates to improve consistency across bylaws."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000025","json":"https://secwatch.observer/filing/0001664710-25-000025.json","markdown":"https://secwatch.observer/filing/0001664710-25-000025.md","text":"https://secwatch.observer/filing/0001664710-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/0001664710-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000025/kros-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T06:20:19.965768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}